Cytosorbents (NASDAQ:CTSO) Earns Hold Rating from Analysts at StockNews.com

Equities researchers at StockNews.com began coverage on shares of Cytosorbents (NASDAQ:CTSO) in a research report issued on Friday. The brokerage set a “hold” rating on the medical research company’s stock.

Other analysts also recently issued reports about the stock. D. Boral Capital reaffirmed a “buy” rating and set a $10.00 price objective on shares of Cytosorbents in a report on Monday, January 13th. HC Wainwright reaffirmed a “neutral” rating and set a $1.00 price objective on shares of Cytosorbents in a report on Monday, November 11th. Two research analysts have rated the stock with a hold rating, two have given a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $4.67.

Cytosorbents Stock Performance

NASDAQ CTSO opened at $1.31 on Friday. Cytosorbents has a 52-week low of $0.70 and a 52-week high of $1.59. The company has a debt-to-equity ratio of 1.06, a quick ratio of 1.58 and a current ratio of 1.97. The company has a market capitalization of $71.63 million, a P/E ratio of -3.64 and a beta of 0.61. The company has a fifty day moving average of $0.98 and a 200-day moving average of $1.04.

Institutional Trading of Cytosorbents

Hedge funds have recently added to or reduced their stakes in the business. Renaissance Technologies LLC lifted its stake in Cytosorbents by 10.6% in the fourth quarter. Renaissance Technologies LLC now owns 88,020 shares of the medical research company’s stock worth $80,000 after purchasing an additional 8,400 shares during the last quarter. Raymond James Financial Inc. bought a new stake in Cytosorbents in the fourth quarter worth $99,000. Geode Capital Management LLC raised its stake in shares of Cytosorbents by 7.5% during the third quarter. Geode Capital Management LLC now owns 467,058 shares of the medical research company’s stock valued at $701,000 after acquiring an additional 32,415 shares during the last quarter. Sargent Investment Group LLC raised its stake in shares of Cytosorbents by 13.4% during the third quarter. Sargent Investment Group LLC now owns 1,626,247 shares of the medical research company’s stock valued at $2,439,000 after acquiring an additional 192,747 shares during the last quarter. Finally, Skylands Capital LLC raised its stake in shares of Cytosorbents by 1.0% during the fourth quarter. Skylands Capital LLC now owns 2,781,622 shares of the medical research company’s stock valued at $2,531,000 after acquiring an additional 26,195 shares during the last quarter. 32.87% of the stock is owned by institutional investors.

Cytosorbents Company Profile

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals.